There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...
Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
Single-cell analysis is reshaping drug discovery, but interpretation remains slow. AI single cell approaches may close the ...
Gilead Sciences is entering a pivotal moment in its evolution. Long defined by its dominance in antivirals, particularly for HIV, the company now faces a strategic challenge: the need to meaningfully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results